Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

This will boost Clarity’s current network of U.S. suppliers for the diagnostic isotope, as the company progresses late-stage clinical trials and works towards commercialisation of its Targeted Copper Theranostics (TCTs).

Nusano is capable of producing 1,000 Ci (37,000 GBq) of copper-64 per day at capacity from its facility in Utah, translating into more than 18,000 patient doses per day at 200 MBq per dose, with a 48-hour shelf-life. This is far in excess of commercial-scale demands across multiple large indications.

Executive chairperson Dr Alan Taylor said the agreement was an important step for the company. “The signing of this Supply Agreement with Nusano will complement Clarity’s existing network of U.S.-based copper-64 suppliers, providing capacity to ensure abundant and seamless supply of the isotope,” he said.

“As Clarity is generating exceptional data in a number of late-stage clinical trials, we now also have a cost-effective, large-scale supply strategy locked in for the commercial roll-outof our Targeted Copper Theranostics in the largest healthcare market in the world, the U.S.”

More market news

Kowtow: “Biggest day in financial history” on Trump’s tariffs retreat

Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst

He continued: “This agreement is an important part of a larger commercial manufacturing strategy, which we will continue implementing as we get closer to the filing of New Drug Applications with the US FDA.”

CU6 shares traded at $1.94 – a rise of 15.63% since the market opened.

Join the discussion: See what HotCopper users are saying about Clarity Pharmaceuticals and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

The agreement – signed between the university and Pro Medicus’ U.S. subsidiary Visage Imaging, Inc. – will provide a framework through which the two parties will collaborate on the development and commercialisation of the platform, looking specifically into its artificial intelligence capabilities.

It will also build on a relationship already established with UCSF through an existing agreement related to Pro Medicus’ Visage 7 Viewer product.

Visage Imaging Global CTO Malte Westerhoff said the partnership around Visage AI Accelerator was a very important milestone.

“Our AI Accelerator program was designed to closely align Visage’s engineering and product development capability with clinical research partners such as UCSF who have a depth of clinical knowledge and extensive research expertise,” he said.

More market news

Kowtow: “Biggest day in financial history” on Trump’s tariffs retreat

Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst

Mr Westerhoff continued: “It provides a unique set of tools for data de-identification, collection, curation, analysis and ‘path-to-production’ in research projects bringing the efficiency and speed of Visage technology to research, resulting in a unified link between the two domains.”

PME shares last traded at $210.32 – a fall of 1.22% since the market opened.

Join the discussion: See what HotCopper users are saying about Pro Medicus and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

The agreements – secured through global tool manufacturer Positec – provide Stealth with exclusive selling rights across all market channels for 5 years in the case of Wesco and Harden Hand Tools, alongside a 3-year term for CAT Power Tools.

This will be done through Stealth’s multiple retail channels, which include company owned stores, reseller stores in trade and retail – including network licensee member stores, B2B sales contact centres and field sales representatives, and online sales channels.

Managing director and CEO Mike Arnold said the agreement marked a ‘game-changing’ milestone for Stealth, particularly within the framework of its FY28 growth plan.

“Securing the exclusive distribution rights for these leading brands highlights our commitment to delivering high-quality products, greater value, and enhanced experiences to our customers, while strengthening our market position and accelerating our FY28 growth ambitions,” he said.

“Annual contract purchasing commitments are set to increase year-on-year as we penetrate markets and channels.

“By the FY28 period, commitments across the three contracts, extrapolated into wholesale-level sales guidance based on projected sell-through, are expected to exceed $30 million, with strong margin contributions above 40%, excluding additional margins from company-owned retail stores.”

The company’s revenue target – according to the FY28 plan – is $300 million.

At 16:40 AEDT, shares in Stealth were trading at 73 cents – a rise of 15.87% since the market opened.

Join the discussion: See what HotCopper users are saying about Stealth and be part of the conversations that move the markets.

According to the exclusive development and license agreement, FUSO Pharmaceutical Industries Ltd will acquire exclusive rights to develop, register, and commercialise DMX-200 in Japan, taking on all clinical trial costs within the country.

The candidate is currently in global Phase 3 clinical development, with a blinded interim analysis expected in August 2025.

Dimerix – which retains all commercialisation rights for DMX-200 in all territories otherthan those covered by its agreements with FUSO, Advanz Pharma, and Taiba – will receive up to ¥10.5 billion (A$1071M) in upfront, development, and sales milestone payments, as well as through royalties.

CEO and managing director Dr Nina Webster said Dimerix was pleased to enter this partnership for the development of the candidate in Japan.

“FUSO brings a wealth of experience in pharmaceutical development and sales and marketing across Japan, and with a proven record in sales and marketing products for patients with renal disease,” she said.

“This partnership reflects a confidence not only in the significant potential for DMX-200 in FSGS patients but also in Dimerix’s capabilities in the development of DMX-200.

“FUSO’s expertise and resources will be invaluable in supporting Dimerix to advance our shared goal of developing and commercialising DMX-200 and bringing hope to those patients desperately in need of treatment options.”

Dimerix shares rose on the news, and at 10:35 AEDT, they were trading at 42.5 cents – a rise of 19.72% since the market opened.

Join the discussion: See what HotCopper users are saying about Dimerix Ltd and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

The deal – expected to net more than $400 million in annual revenue for Ventia – will involve honing the delivery of design, construction, and maintenance of infrastructure, including lifecycle management across Australia and fixed network services for Telstra’s digital infrastructure facilities.

Additionally, Ventia will be involved in the designing and construction of asset relocation and commercial works, as well as the continuation of some services related to network design and construction.

Wideband, optical fibre, data, IP networks, and wireless plans are all included in the deal.

Ventia CEO and Managing Director, Dean Banks, said the deal would build on an already strong business relationship with the telecommunications giant.

“We are proud to have been a trusted partner to Telstra for nearly 30 years and we are excited to expand our partnership to support their strategic goals,” he said.

Existing contracts between the two companies are set to expire in December, and works under the new contract will begin in early 2025.

Ventia has been trading at $3.45.

Join the discussion: See what HotCopper users are saying about Ventia and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

The company aims to introduce the product, SPONTAN, to the market, while also gathering real-world patient data. For this, a partnership with MHDU – which is responsible for an Australia-wide network of pharmacists, GPs, nurses, and allied health professionals working around urological healthcare – will be a boon.

LTR Pharma will also have access to MHDU’s extensive referral network, which includes general practitioners, urologists, and sexual health clinics – with more than 1,000 patients seen annually through the latter.

MHDU founder and executive chairman Brad Butt said this agreement was an important step for both parties.

“This collaboration with LTR Pharma enhances our ability to provide innovative solutions for men’s health concerns,” he said.

“SPONTAN’s rapid-onset profile addresses a significant unmet need in erectile dysfunction treatment, complementing our multi-disciplinary and multi-modal approach to men’shealthcare.”

LTR Pharma has been trading at 84 cents.

Join the discussion: See what HotCopper users are saying about LTR Pharma and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.